FDA Determines Regulatory Review Period for Vandetanib Patent Extension

Summary

The US Food and Drug Administration has officially confirmed the regulatory review period for Vandetanib, a human drug product, in accordance with patent extension regulations, following a submission to the US Patent and Trademark Office.